ChromaDex (NASDAQ: CDXC) reported Q4 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $15.4 million versus the consensus estimate of $15.36 million.

Fourth Quarter 2020 and Recent Highlights

• Total net sales of $15.4 million, up 18% from $13.1 million in the year ago quarter.
• Tru Niagen® net sales of $12.3 million, a 21% increase from the year ago quarter.
• Gross margin of 61.0%, a 400 basis point increase from the year ago quarter.
• Net loss was ($6.1) million or ($0.10) per share, an improvement of $0.05 per share year-over-year.
• Adjusted EBITDA excluding total legal expense, a non-GAAP measure, was a loss of ($1.1) million, a $1.0 million improvement year-over-year.
• Growing body of clinical research suggests that nicotinamide riboside (“NR”) may support important areas of human health.
• Phase 2 clinical study showed a reduction in liver fat and inflammatory markers in patients with non-alcoholic fatty liver disease (NAFLD) when receiving a nutritional protocol that included NR.
• Phase 3 clinical study on 300 patients in Turkey with mild-to-moderate COVID-19 showed a 3.5 day reduction in recovery time when adding a daily nutritional protocol that included NR to the local standard of care.
• Tru Niagen® received the ‘Most Favourite Brand’ award by Watsons Hong Kong loyalty members for the second consecutive year.

“ChromaDex’s philosophy of focusing on business fundamentals with a science-based strategic approach continued in 2020,” said ChromaDex CEO Rob Fried. “In 2021, we will further our position as the world's leading NAD+ company by growing the Tru Niagen® brand, extending partnerships and furthering scientific advancements with world-leading scientists."

2021 Outlook

Looking forward, the Company expects continued, steady revenue growth driven by its global ecommerce business, as well as growth with existing and new strategic partners. The Company expects continued gross margin improvement to slightly better than 60%, and roughly flat selling and marketing and R&D expense as a percentage of net sales year-over-year. The Company expects slightly higher general and administrative expense, excluding severance, restructuring and legal expense. The Company plans to increase investments and resources to drive brand awareness and accelerate its R&D pipeline to capitalize on growth in the NAD+ market globally.

For earnings history and earnings-related data on ChromaDex (CDXC) click here.